Xeris Biopharma: Checking-In On One Of My 'Top Ideas' [Seeking Alpha]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growth. Risks include competition from larger healthcare companies and the FDA approval of a generic version of one of Xeris' products, Keveyis. Looking for a portfolio of ideas like this one? Members of Compounding Healthcare get exclusive access to our subscriber-only portfolios. Learn More » It has been over a year since my last Xeris Biopharma ( NASDAQ: XERS article , where I reviewed the company's 2022 achievements including record net product revenue, driven by robust growth in our approved product portfolio. In addition, I also pointed out that company management was confident in their trajectory toward cash flow breakeven by the end of 2023. At that time, XERS was trading near $1.25 per share with a market cap of approximately $189M, I observed a notable disparity between the stock's valuation and its growth potential. As a result, I stood firm with the choice to k
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions [Yahoo! Finance]Yahoo! Finance
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business Wire
- Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire
- Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $5.00 price target on the stock.MarketBeat
- Here's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Results [Yahoo! Finance]Yahoo! Finance
XERS
Earnings
- 3/6/24 - Miss
XERS
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- XERS's page on the SEC website